KeraStat(R) Cream for Radiation Dermatitis
| Status: | Recruiting |
|---|---|
| Conditions: | Dermatology, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 6/20/2018 |
| Start Date: | April 11, 2018 |
| End Date: | September 30, 2018 |
| Contact: | Emily Teal, MA |
| Email: | eteal@wakehealth.edu |
| Phone: | 336-713-6908 |
Pilot Study: KeraStat(R) Cream for Radiation Dermatitis
The primary objectives of the proposed research are to evaluate patient use of KeraStat Cream
and collect data to inform a larger future trial.
The secondary objectives are to assess the safety and tolerability of KeraStat Cream in
subjects at risk of radiation dermatitis, to assess the effectiveness of KeraStat Cream and
how that compares to the current standard of care, and to estimate the amount of KeraStat
Cream used per patient and coverage on skin.
and collect data to inform a larger future trial.
The secondary objectives are to assess the safety and tolerability of KeraStat Cream in
subjects at risk of radiation dermatitis, to assess the effectiveness of KeraStat Cream and
how that compares to the current standard of care, and to estimate the amount of KeraStat
Cream used per patient and coverage on skin.
Inclusion Criteria:
1. Age 18 to 70
2. Female
3. Diagnosis of breast cancer and scheduled to receive 4 to 6 weeks of radiation therapy
(radiation dose of 42 Gy or more)
4. Able and willing to sign protocol consent form
5. Able and willing to document symptoms and treatment details as often as needed, not to
exceed daily notes
6. Able and willing to have photographs of the affected area taken regularly
Exclusion Criteria:
1. Women who are pregnant, lactating/nursing or plan to become pregnant
2. Previous radiation therapy to the area to be treated with radiation therapy
3. Receiving palliative radiation therapy
4. Unhealed or infected surgical sites in the irradiation area
5. Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall
treatment plan (tamoxifen/aromatase inhibitor allowed)
6. Use of oral corticosteroids or topical corticosteroids in the irradiation area
7. Autoimmune disease
8. Skin disease in target irradiation area
9. Known allergy to the standard of care or ingredients in KeraStat Cream
We found this trial at
1
site
Winston-Salem, North Carolina 27157
Principal Investigator: Karen Winkfield, MD PhD
Phone: 336-713-6908
Click here to add this to my saved trials
